5Agal S,Baiial R,Pramanik S,et al.Monitoring and manage-ment of antituberculosis drug induced hepatotoxicity[J].J Gas-troenterol Hepatol,2005,20(11):1745-1752.
6Sang-Heon Kim,Sang-Hoon Kim,Ho Joo Yoon,et al.GSTTland GSTMl null mutations and adverse reactions induced by an-tituberculosis drugs in Koreans[J].Tuberculosis,2010,90(1):39-43.
7Bose PD,Sarma MP,Medhi S,et al.Role of polymorphic N-ac-etyl transferase2 and cytochrome P4502EI gene in antituberculo-sis treatment-induced hepatitis[J].J Gastroenterol Hepatol,2011,26(2):312-318.
8Saukkonen JJ,Cohn DL,Jasmer RM,et al.An official ATS statement:hepatotoxicity of antituberculosis therapy[J].Am J Resp ir Crit Care Med,2006,174(8):935-952.
9Sharma SK,Balamurugan A,Saha PK,et al.Evaluation of clin-ical and immunogenetic risk factors for the development of hepa-totoxicity during anti-tuberculosis treatment[J].Am J Respir Crit Care Med,2002,166(7):916-919.
10Yee D,Valiquette C,Pelletier M,et al.Incidence of serious side effects from first-line anlituberculosis drugs among patients trea-ted for active tuberculosis[J].Am J Respir Crit Care Med,2003,167(11):1472-1477.
